Country: Canada
Language: English
Source: Health Canada
SELEGILINE HYDROCHLORIDE
MYLAN PHARMACEUTICALS ULC
N04BD01
SELEGILINE
5MG
TABLET
SELEGILINE HYDROCHLORIDE 5MG
ORAL
60
Prescription
MONOAMINE OXIDASE B INHIBITORS
Active ingredient group (AIG) number: 0131374001; AHFS:
CANCELLED POST MARKET
2017-08-02
1 PRODUCT MONOGRAPH MYLAN-SELEGILINE (SELEGILINE HYDROCHLORIDE) 5 MG TABLETS ANTIPARKINSONIAN AGENT Mylan Pharmaceuticals ULC Date of Preparation: 85 Advance Road July 15, 2009 Etobicoke, Ontario M8Z 2S6 Date of Revision: Control#: 131229 2 PRODUCT MONOGRAPH MYLAN-SELEGILINE (SELEGILINE HYDROCHLORIDE) TABLETS - 5 MG THERAPEUTIC CLASSIFICATION ANTIPARKINSONIAN AGENT CLINICAL PHARMACOLOGY Selegiline hydrochloride, previously known as l-deprenyl hydrochloride, a synthetic selective inhibitor of the MAO-B enzyme when administered at the recommended doses, has been found to be of value as an adjunct to the management of some patients with Parkinson's Disease when administered as add-on therapy to levodopa/carbidopa. The mechanism of action of selegiline hydrochloride responsible for its action as an adjunct in the symptomatic management of selected Parkinsonian patients is not well understood. Inhibitors of type MAO-B enzyme may be useful by blocking the metabolism of dopamine and by increasing the net amount of dopamine available. It may increase dopaminergic activity by blocking dopamine uptake at the synapses. Two principal metabolites of selegiline hydrochloride, l-amphetamine and l-metamphetamine (which with l- desmethylselegiline account for 44% of dose administered, as excreted metabolites) could also play a role. They interfere with neuronal uptake. By inhibiting MAO-B enzyme, selegiline hydrochloride may prevent the generation of free radicals and hydrogen peroxide resulting from oxidation of dopamine. It may also prevent the conversion of MPTP to MPP. Non-selective 3 inhibitors of MAOs which inhibit MAO-A enzymes are not used in the management of Parkinson patients because of side effects, such as hypertension, increase in involuntary movements and toxic delirium. Toxic delirium has also been reported with selegiline hydrochloride when used as adjunctive therapy to levodopa treatment. HYPERTENSIVE CRISIS ("CHEESE REACTION"). The MAOs are currently subclassified into two types, A and B, which differ in their Read the complete document